鉄 : 休止期脱毛症
B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。合計11,067名の参加者を対象とした56件の研究(RCT 2件を含む)に基づく。研究間で結果にばらつきが見られる。
結論
Iron may support recovery from telogen effluvium, particularly when low ferritin levels are confirmed, but the evidence is mixed and routine supplementation without testing is not well-supported.
- 56 studies provide substantial evidence, though results are mixed across the research
- Lower ferritin levels are commonly found in patients with telogen effluvium
- One study found iron supplementation improved satisfaction even in patients without overtly low ferritin
- Blood testing for ferritin and iron levels is recommended before starting supplementation
Key Study Findings
対象集団: women with androgenetic alopecia (female pattern hair loss)
Key Statistics
62
研究数
11072
参加者数
Mixed
グレード
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 18 mg/day (women)
- deficiency:
- 65-200 mg elemental iron/day
上限量: 45 mg/day
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Neutral | -- |
| variable; exosomes predominantly from mesenchymal stem cells (MSCs) | -- | Positive | 16 |
| None | -- | Mixed | -- |
| None | -- | Neutral | 2851 |
| Various microtrauma procedures: microneedling, fractional/non-fractional lasers, contact immunothera | -- | Positive | -- |
| None | -- | Positive | -- |
| not applicable (observational; serum ferritin measured) | -- | Negative | 100 |
| None | -- | Mixed | -- |
推奨摂取タイミング: On an empty stomach with vitamin C for best absorption; take 2 hours apart from calcium
Safety & Side Effects
報告されている副作用
- ⚠ Constipation (most common)
- ⚠ Nausea and stomach cramps
- ⚠ Dark or black stools
- ⚠ Iron overload with excessive supplementation (hemochromatosis risk)
既知の相互作用
- ● Calcium supplements and dairy (reduce iron absorption by 50-60%)
- ● Proton pump inhibitors (omeprazole) and H2 blockers reduce absorption
- ● Tetracycline and quinolone antibiotics (mutual absorption reduction)
- ● Levothyroxine (iron reduces thyroid hormone absorption)
耐容上限摂取量: 45 mg/day
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does 鉄 help with 休止期脱毛症?
How much 鉄 should I take for 休止期脱毛症?
Are there side effects of 鉄?
How strong is the evidence for 鉄 and 休止期脱毛症?
Related Evidence
References
- [1] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
- [2] Fatemeh Chinisaz et al.. Obes Surg. 2026. Comparative Analysis of Postoperative Hair Loss and Micronutrient Deficiencies After One-Anastomosis Gastric Bypass Versus Sleeve Gastrectomy. doi:10.1007/s11695-026-08597-2 PubMed
- [3] Sarah Schaffer et al.. Cureus. 2025. A Scoping Review of Exosome Delivery Applications in Hair Loss. doi:10.7759/cureus.81152 PubMed
- [4] Ömer Karakoyun et al.. J Cosmet Dermatol. 2025. Retrospective Review of 2851 Female Patients With Telogen Effluvium: A Single-Center Experience. doi:10.1111/jocd.70037 PubMed
- [5] Andrea Sechi et al.. Nutrients. 2025. Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients. doi:10.3390/nu17091451 PubMed
- [6] Luis A Mendoza et al.. Cureus. 2025. Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation. doi:10.7759/cureus.82991 PubMed
- [7] Xuexue Pan et al.. Aesthetic Plast Surg. 2025. Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. doi:10.1007/s00266-025-05077-3 PubMed
- [8] Rui-Xian Guo et al.. Front Pharmacol. 2025. Research progress in the treatment of non-scarring alopecia: mechanism and treatment. doi:10.3389/fphar.2025.1544068 PubMed
- [9] Woo C Tay et al.. Ital J Dermatol Venerol. 2025. The role of microtrauma in hair regrowth and regeneration in non-scarring alopecia. doi:10.23736/S2784-8671.25.08232-5 PubMed
- [10] Adam Leavitt et al.. J Drugs Dermatol. 2025. Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions. doi:10.36849/JDD.8763 PubMed
- [11] Namrata Chhabra et al.. Int J Trichology. 2025. Telogen Effluvium Following Coronavirus Disease-2019 Infection: A Retrospective Study of 113 Cases. doi:10.4103/ijt.ijt_38_22 PubMed
- [12] Nishantan Thamotharan et al.. Cureus. 2025. Assessment of Serum Ferritin Levels in Female Patients With Telogen Effluvium. doi:10.7759/cureus.100249 PubMed
- [13] Barbara Owecka et al.. Biomedicines. 2024. The Hormonal Background of Hair Loss in Non-Scarring Alopecias. doi:10.3390/biomedicines12030513 PubMed
- [14] Irem Nur Durusu Turkoglu et al.. J Cosmet Dermatol. 2024. A comprehensive investigation of biochemical status in patients with telogen effluvium: Analysis of Hb, ferritin, vitamin B12, vitamin D, thyroid … doi:10.1111/jocd.16512 PubMed
- [15] Shuxuan Li et al.. Int J Pharm. 2024. Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation. doi:10.1016/j.ijpharm.2024.124585 PubMed
- [16] Nermeen Ibrahim Bedair et al.. Arch Dermatol Res. 2024. Post Covid telogen effluvium: the diagnostic value of serum ferritin biomarker and the preventive value of dietary supplements. a case … doi:10.1007/s00403-024-03004-1 PubMed
- [17] Boutros Soutou et al.. Indian J Dermatol. 2024. Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study. doi:10.4103/ijd.ijd_744_22 PubMed
- [18] Xuefei Zhang et al.. Int J Nanomedicine. 2024. Resveratrol-Loaded Versatile Nanovesicle for Alopecia Therapy via Comprehensive Strategies. doi:10.2147/IJN.S477820 PubMed
- [19] Rhiannon C Miller et al.. Arch Dermatol Res. 2024. Cost-effectiveness analysis of laboratory monitoring in newly diagnosed telogen effluvium patients. doi:10.1007/s00403-024-02948-8 PubMed
- [20] Leyla Bilik et al.. North Clin Istanb. 2024. Evaluation of the relationship of digital phototrichogram findings of patients with diffuse hair loss with blood TSH, ferritin and vitamin … doi:10.14744/nci.2023.33269 PubMed
- [21] Massimo Milani et al.. Skin Res Technol. 2023. Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair … doi:10.1111/srt.13381 PubMed
- [22] Vivien Chen et al.. Pediatr Dermatol. 2023. Etiology, management, and outcomes of pediatric telogen effluvium: A single-center study in the United States. doi:10.1111/pde.15154 PubMed
- [23] Rhiannon C Miller et al.. J Am Acad Dermatol. 2023. "Shedding" low yield testing for telogen effluvium: A cross-sectional study of 16,381 laboratory results from newly diagnosed patients. doi:10.1016/j.jaad.2023.05.045 PubMed
- [24] Hakan Arslan et al.. Dermatol Pract Concept. 2023. Micronutrient Deficiencies and Digital Computerized Phototrichogram Analysis in Telogen Effluvium: a Retrospective Correlation Study in a Tertiary Medical Center. doi:10.5826/dpc.1303a202 PubMed
- [25] Michela Starace et al.. Ital J Dermatol Venerol. 2023. Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic … doi:10.23736/S2784-8671.22.07416-3 PubMed
- [26] Ahu Yorulmaz et al.. J Cosmet Dermatol. 2022. Telogen effluvium in daily practice: Patient characteristics, laboratory parameters, and treatment modalities of 3028 patients with telogen effluvium. doi:10.1111/jocd.14413 PubMed
- [27] Ümran Öner et al.. Turk J Med Sci. 2022. Nonscarring scalp alopecia: Which laboratory analysis should we perform on whom? doi:10.3906/sag-2106-28 PubMed
- [28] Saadet İbiş et al.. Dermatol Pract Concept. 2022. Evaluation of MCV/RDW Ratio and Correlations With Ferritin in Telogen Effluvium Patients. doi:10.5826/dpc.1203a151 PubMed
- [29] Elizabeth J Klein et al.. JAAD Int. 2022. Supplementation and hair growth: A retrospective chart review of patients with alopecia and laboratory abnormalities. doi:10.1016/j.jdin.2022.08.013 PubMed
- [30] Muhammad Fawad Aslam et al.. Cureus. 2022. The Association of Serum Ferritin Levels With Non-scarring Alopecia in Women. doi:10.7759/cureus.32123 PubMed
- [31] Efe Kakpovbia et al.. J Drugs Dermatol. 2021. Laboratory Testing in Telogen Effluvium. doi:10.36849/JDD.5771 PubMed
- [32] Kavita Poonia et al.. J Cosmet Dermatol. 2019. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. doi:10.1111/jocd.12559 PubMed
- [33] Rodney D Sinclair. Int J Dermatol. 2018. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. doi:10.1111/ijd.13838 PubMed
- [34] Flávia Alvim Sant'Anna Addor et al.. Clin Cosmet Investig Dermatol. 2018. Comparative evaluation between two nutritional supplements in the improvement of telogen effluvium. doi:10.2147/CCID.S173082 PubMed
- [35] Ibrahim Halil Yavuz et al.. Indian J Dermatol. 2018. Assessment of Heavy Metal and Trace Element Levels in Patients with Telogen Effluvium. doi:10.4103/ijd.IJD_610_17 PubMed
- [36] Dinesh Gowda et al.. Int J Trichology. 2017. Prevalence of Nutritional Deficiencies in Hair Loss among Indian Participants: Results of a Cross-sectional Study. doi:10.4103/ijt.ijt_48_16 PubMed
- [37] Evelyn J Cheung et al.. J Drugs Dermatol. 2016. Vitamin and Mineral Deficiencies in Patients With Telogen Effluvium: A Retrospective Cross-Sectional Study. PubMed
- [38] Tee Wei Siah et al.. Int J Trichology. 2016. Female Pattern Hair Loss: A Retrospective Study in a Tertiary Referral Center. doi:10.4103/0974-7753.188033 PubMed
- [39] Kirti Deo et al.. Dermatol Res Pract. 2016. Clinicoepidemiological Observational Study of Acquired Alopecias in Females Correlating with Anemia and Thyroid Function. doi:10.1155/2016/6279108 PubMed
- [40] Caroline Bittencourt et al.. Int J Dermatol. 2016. Non-invasive method distinguishes chronic telogen effluvium from mild female pattern hair loss: clinicopathological correlation. doi:10.1111/ijd.13200 PubMed
- [41] Jana Zímová et al.. Acta Dermatovenerol Croat. 2016. Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl. PubMed
- [42] Shashikant Malkud. J Clin Diagn Res. 2015. Telogen Effluvium: A Review. doi:10.7860/JCDR/2015/15219.6492 PubMed
- [43] Jay C Vary. Med Clin North Am. 2015. Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. doi:10.1016/j.mcna.2015.07.003 PubMed
- [44] Shashikant Malkud. J Clin Diagn Res. 2015. A Hospital-based Study to Determine Causes of Diffuse Hair Loss in Women. doi:10.7860/JCDR/2015/14089.6170 PubMed
- [45] Abeer M Abdel Aziz et al.. Int J Trichology. 2015. Possible Relationship between Chronic Telogen Effluvium and Changes in Lead, Cadmium, Zinc, and Iron Total Blood Levels in Females: A … doi:10.4103/0974-7753.167465 PubMed
- [46] Katya L Harfmann et al.. Clin Obstet Gynecol. 2015. Hair loss in women. doi:10.1097/GRF.0000000000000081 PubMed
- [47] Nicolas Perez-Mora et al.. Dermatol Ther. 2014. Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications. doi:10.1111/dth.12101 PubMed
- [48] Thamer Mubki. J Cutan Med Surg. 2014. Use of Vitamins and Minerals in the Treatment of Hair Loss: A Cross-Sectional Survey among Dermatologists in Saudi Arabia. doi:10.2310/7750.2014.14008 PubMed
- [49] Hatice Uce Özkol et al.. Turk J Med Sci. 2014. Is TrichoScan a new diagnostic method for diffuse hair loss? doi:10.3906/sag-1212-78 PubMed
- [50] Maria Rogalidou et al.. Ann Gastroenterol. 2014. Telogen effluvium as the first symptom of Crohn's disease in a child. PubMed
- [51] H Rasheed et al.. Skin Pharmacol Physiol. 2013. Serum ferritin and vitamin d in female hair loss: do they play a role? doi:10.1159/000346698 PubMed
- [52] Khitam Al-Refu. Int J Trichology. 2013. Hair loss in children: common and uncommon causes; clinical and epidemiological study in jordan. doi:10.4103/0974-7753.130393 PubMed
- [53] Elise A Olsen et al.. J Am Acad Dermatol. 2010. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. doi:10.1016/j.jaad.2009.12.006 PubMed
- [54] Shyam Behari Shrivastava. Indian J Dermatol Venereol Leprol. 2009. Diffuse hair loss in an adult female: approach to diagnosis and management. doi:10.4103/0378-6323.45215 PubMed
- [55] N V Tsiskarishvili et al.. Georgian Med News. 2007. [Effectiveness of the treatment plan for androgenetic alopecia]. PubMed
- [56] Leonid Benjamin Trost et al.. J Am Acad Dermatol. 2006. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. doi:10.1016/j.jaad.2005.11.1104 PubMed
- [57] Maria K Hordinsky. Semin Cutan Med Surg. 2006. Medical treatment of noncicatricial alopecia. doi:10.1016/j.sder.2006.01.007 PubMed
- [58] Renata Strumia. Am J Clin Dermatol. 2005. Dermatologic signs in patients with eating disorders. doi:10.2165/00128071-200506030-00003 PubMed
- [59] Rodney Sinclair. J Am Acad Dermatol. 2005. Chronic telogen effluvium: a study of 5 patients over 7 years. doi:10.1016/j.jaad.2004.05.040 PubMed
- [60] V del Marmol et al.. Rev Med Brux. 2004. [Androgenetic alopecia]. PubMed
- [61] Jonathan Kantor et al.. J Invest Dermatol. 2003. Decreased serum ferritin is associated with alopecia in women. doi:10.1046/j.1523-1747.2003.12540.x PubMed
- [62] D H Rushton et al.. Int J Cosmet Sci. 2002. Causes of hair loss and the developments in hair rejuvenation. doi:10.1046/j.0412-5463.2001.00110.x PubMed
- [63] D H Rushton. Dermatol Clin. 1993. Management of hair loss in women. PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。